CF
RARE icon

CNA Financial’s Ultragenyx Pharmaceutical RARE Stock Holding History

CNA Financial’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-5,310
Closed -$220K – 142
2022
Q3 		$220K Buy
5,310
+420
+9% +$21.6K 0.08% 161
2022
Q2 		$292K Sell
4,890
-640
-12% -$39.4K 0.1% 159
2022
Q1 		$402K Sell
5,530
-40
-0.7% -$2.78K 0.12% 159
2021
Q4 		$468K Buy
5,570
+390
+8% +$31.7K 0.12% 165
2021
Q3 		$467K Sell
5,180
-1,610
-24% -$146K 0.13% 167
2021
Q2 		$647K Sell
6,790
-170
-2% -$17.7K 0.18% 146
2021
Q1 		$792K Sell
6,960
-310
-4% -$42.2K 0.24% 127
2020
Q4 		$1.01M Sell
7,270
-870
-11% -$103K 0.32% 93
2020
Q3 		$669K Buy
8,140
+10
+0.1% +$829 0.25% 108
2020
Q2 		$636K Buy
+8,130
New +$538K 0.25% 105

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

CNA Financial's RARE Position: Q4 2022 in Review

CNA Financial sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2022, closing a stake of 5,310 shares — an estimated $220K sold.

CNA Financial first reported a position in RARE in Q2 2020 and held it in 10 quarters. The position peaked at $1.01M in Q4 2020. 227 funds tracked by Wall St. Rank hold RARE as of Q4 2022.

  • CNA Financial reported no remaining Ultragenyx Pharmaceutical position as of Q4 2022 after selling out during the quarter.
  • CNA Financial sold 5,310 Ultragenyx Pharmaceutical shares in Q4 2022, an estimated $220K.
  • CNA Financial first reported a position in Ultragenyx Pharmaceutical in Q2 2020 and held it in 10 quarters.
  • CNA Financial's Ultragenyx Pharmaceutical position peaked at $1.01M in Q4 2020.
  • 227 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2022.

Based on CNA Financial's 13F filing for Q4 2022, filed 10 Feb 2023.